Piper Sandler Downgrades Iovance Biotherapeutics to Neutral, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has downgraded Iovance Biotherapeutics (NASDAQ:IOVA) from Overweight to Neutral and lowered the price target from $19 to $10.
July 29, 2024 | 9:37 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler downgraded Iovance Biotherapeutics from Overweight to Neutral and reduced the price target from $19 to $10, indicating a less optimistic outlook.
The downgrade from Overweight to Neutral and the significant reduction in the price target from $19 to $10 by Piper Sandler suggests a less favorable view of Iovance Biotherapeutics' near-term prospects. This is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100